Browse by Poster Presenter

Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Y
Yan, Diqin

Clinical Trial Institution, Peking University People's Hospital
(T-133) Placebo Response Model for Alopecia Areata: A Model-based Meta-analysis of Randomized Controlled Trials
Diqin Yan
Favorite
Yang, Feng

Astrazeneca
(W-135) PharmaInsight Explorer: Empowering EDA in Clinical Pharmacology and Safety Science
Feng Yang
Favorite
Yang, Janice

Icahn School of Medicine at Mount Sinai
(M-127) Creating Cell-specific Computational Models of Stem Cell-derived Cardiomyocytes Using Optical Experiments
Janice Yang
Favorite
Yang, Tae Eun

Johnson & Johnson Innovative Medicine
(M-128) Population Pharmacokinetic Analysis of Guselkumab in Adults with Moderately to Severely Active Crohn’s Disease
Tae Eun Yang
Favorite
Yang, Xinxin

Bristol Myers Squibb
(M-129) Automating Translational Physiologically Based Pharmacokinetic Modeling with R and Simcyp: An Innovative Approach
Xinxin Yang
Favorite
Yan, Xiaoyu

The Chinese University of Hong Kong
(M-032) A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron
Xiaoyu Yan
Favorite
(M-126) A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages
Xiaoyu Yan
Favorite
Yellepeddi, Venkata

Division of Clinical Pharmacology, Spencer Fox Eccles School of Medicine, University of Utah
(T-134) Integrating Physiologically Based Pharmacokinetic (PBPK) Modeling and Strain-Specific Exposure-Efficacy Requirements to Refine the Dosage Regimens for Voriconazole in a Pediatric Cancer Population
Venkata Yellepeddi
Favorite
Yin, Xuefen

University of Florida
(T-135) Potential Bias Evaluation of Conventional Exposure-Response Analysis Methods: A Small Molecule Cancer Drug Example
Xuefen Yin
Favorite
Yoder, Todd

Metrum Research Group
(W-136) Gompertz Cure Rate Survival Models with Stan and Brms
Todd Yoder
Favorite
Yoon, Deok Yong

Novartis
(W-137) Immune thrombocytopenia purpura (ITP) indication extension allowing for administration of Eltrombopag in adult patients who are refractory to 1L-treatment irrespective of time since diagnosis
Deok Yong Yoon
Favorite
Yuan, Dongfen

Janssen Research & Development
(M-132) Population Pharmacokinetics and Exposure-Response Relationship of Amivantamab in Combination with Carboplatin-Pemetrexed: Analyses from PAPILLON Supporting the Weight-Tiered Q3W Regimen
Dongfen Yuan
Favorite
Yuan, Lin

Fractal Therapeutics
(W-138) A model-based framework for assessing schedule dependence of therapeutic window for three-drug combinations
Lin Yuan
Favorite
(W-139) Design and evaluation of a novel decision metric for estimating Phase 1 Maximum Tolerated Dose
Lin Yuan
Favorite
Yuan, Xuanzhen

College of Pharmacy, University of Iowa
(M-133) Utilizing Opportunistic Clinical Study and Population-Based Pharmacometric Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients
Xuanzhen Yuan
Favorite
Yu, Ruihong

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, 14214, USA
(M-130) Across-species meta-analysis of methylprednisolone reversible metabolism and pharmacokinetics utilizing allometric and scaling model approaches
Ruihong Yu
Favorite
(M-131) Physiologically based pharmacokinetic modeling the reversible metabolism and tissue-specific partitioning of methylprednisolone and methylprednisone in rats
Ruihong Yu
Favorite